15 minutes ago
Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.
1 hour ago
In an interview with HCPLive, Larry Ereshefsky, PharmD discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
1 hour ago
2 hours ago
Solomon explains how the health care system contributes to climate change and the direct health impacts seen as a result, based on her session at ACP.
13 hours ago
Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.